



Supplemental Figure 5


A Hess_Targets_Hoxa9-Meis1 UP




B Myc_Target_up (Schuhmacher et al.)




C Mad1_Target_DN (IRITANI et al.)




D RAPAMYCIN_Sensitive (Bilanges et al.)




E Manalo_Hypoxia_DN (Manolo et al.)




F



G



H



Supplemental Figure 5. Gene pathways that were affected by different small molecule inhibitors for MLL-AF9 leukemia. **A-E.** Gene set enrichment analyses (GSEA) evaluating gene signatures regulated by Hoxa9/Meis1 (A), Myc (B), Mad1 (C), or sensitive to Rapamycin (D) or Hypoxia (E) in the RNA-seq analyses of MM-401 treated MLL-AF9 cells. NES, normalized enrichment score; FDR, false-discovery rate. **F-H,** GO term analysis for genes that were regulated by MENIN/DOT1L (F), BRD4 (G) as well as genes that were up regulated by EPZ-5676 and MI-2-2 (H). Genes with log₂ fold change >1 or <-1 were used for analysis.